Premium
Hepatic lipase polymorphism and increased risk of peripheral arterial disease
Author(s) -
ELLER P.,
SCHGOER W.,
MUELLER T.,
TANCEVSKI I.,
WEHINGER A.,
ULMER H.,
FOEGER B.,
HALTMAYER M.,
RITSCH A.,
PATSCH J. R.
Publication year - 2005
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.2005.01549.x
Subject(s) - hepatic lipase , medicine , endocrinology , lipase , odds ratio , lipoprotein lipase , single nucleotide polymorphism , homocysteine , allele , genotype , biology , enzyme , genetics , gene , biochemistry , adipose tissue
. Background. Hepatic lipase plays a key role in the metabolism of pro‐atherogenic and anti‐atherogenic lipoproteins affecting their plasma level as well as their physico‐chemical properties. We hypothesized single nucleotide polymorphisms in the promoter region of the hepatic lipase gene to be associated with an increased risk for peripheral arterial disease (PAD). Methods. A total of 241 patients with PAD and 241 controls matched for sex and age (±2 years) were genotyped cross‐sectionally for the −250 single nucleotide polymorphism in the hepatic lipase promoter. Results. The frequency for the −250A allele in patients with PAD was 0.203, whereas it was 0.147 in the controls ( P = 0.022). Hepatic lipase promoter polymorphism distribution remained significantly different between cases and controls after multivariate logistic regression analysis ( P = 0.021). The odds ratio of the −250A hepatic lipase allele for the PAD was 1.69 (95% confidence interval of 1.08–2.64), when adjusted for current smoking, arterial hypertension, cholesterol, triglycerides, HbA 1C , total homocysteine and high sensitivity C‐reactive protein. Conclusion. Previous data in patients with ischaemic heart disease have suggested a pro‐atherogenic role of low hepatic lipase levels. Our results extend these data to the vascular territory of the lower limbs, such that hepatic lipase promoter variation represents a genetic risk factor of PAD.